• David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit
• Evolus' flagship product, Jeuveau^® is the fastest growing aesthetic toxin in the U.S. for the last three years¹

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its participation in the Women’s Wear Daily (WWD) Beauty CEO Summit. This summit brings together the leading retailers, marketers, and creative minds across all categories to help prepare for the next phase of global beauty while driving growth and innovation today. At the global consumer beauty event, President and Chief Executive Officer David Moatazedi is the first medical aesthetics leader to be a speaker in a conversation with WWD Editor-in-Chief Jenny Fine. Today also marks the fifth anniversary since the launch of Evolus’ flagship neurotoxin, Jeuveau^®, which is the fastest growing toxin brand in the U.S. for the last three years¹.

"I am excited to lead a company in an industry that stands at the intersection of beauty and medical aesthetics, that we define as performance beauty,” said David Moatazedi, President and Chief Executive Officer of Evolus. “Empowering individuals and redefining beauty through our differentiated approach fuels our presence at this global event, which is underscored by the strength of our brand and our focus on the younger generation.”

“We are excited to have David Moatazedi on the mainstage at the WWD Beauty CEO Summit,” said Amanda Smith, President, Fairchild Media Group. “Evolus is becoming a real changemaker in the beauty aesthetics space and we look forward to bringing this science-driven innovation conversation to the WWD global thought leader audience.”

Moatazedi continued, “Reflecting on five years of progress, I am proud of what we have accomplished in such a short period of time with our flagship product, Jeuveau^®. As we celebrate this important milestone, I am excited about the momentum we have built and our evolution from a single-product aesthetics company to a multi-product performance beauty innovator.”

The fireside chat can be accessed on the Investor Relations page of the Evolus website here, which will be made available next week. A replay of the webcast will be available for 90 days after the date of the presentation.

¹ Measured by comparing year-over-year revenue growth of each aesthetic neurotoxin on the market for the entirety of each comparable year.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure^™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse^™, and the exclusive distributor in Europe of Estyme^®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® and Nuceiva^®, are registered trademarks and Evolysse^™ is a trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Estyme^® is a trademark of Symatese Aesthetics S.A.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515169929/en/